Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission

Bipolar Disorders

Volumn 16, Issue 8, 2014, Pages 800-808

  Tsai, Shang Ying ^a,b   Chung, Kuo Hsuan ^a,b   Huang, Shou Hung ^a,b   Chen, Pao Huan ^a,b   Lee, Hsin Chien ^a   Kuo, Chian Jue ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Bipolar depression; High sensitivity C reactive protein (hs CRP); Inflammation; Interleukin 1 receptor antagonist (IL 1Ra); sIL 6R; Soluble interleukin 2 receptor (sIL 2R); Soluble tumor necrosis factor receptor 1 (sTNF R1)

Indexed keywords

C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR; LEPTIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE INTERLEUKIN 6 RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INSULIN RESISTANCE; MALE; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; REMISSION;

EID: 84913615746     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12240     Document Type: Article

References (50)

1. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009; 70: 1078-1090.
2. Berk M, Brnabic A, Dodd S et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord 2011; 13: 87-98.
3. Brietzke E, Stertz L, Fernandes BS et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009; 116: 214-217.
4. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110-116.
5. Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ. Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord 2001; 64: 185-193.
6. Tsai SY, Lee HC, Chen CC, Lee CH. Plasma levels of soluble transferrin receptors and Clara cell protein (CC16) during bipolar mania and subsequent remission. J Psychiatr Res 2003; 37: 229-235.
7. Hope S, Melle I, Aukrust P et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009; 11: 726-734.
8. Hope S, Dieset I, Agartz I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45: 1608-1616.
9. Barbosa IG, Huguet RB, Mendonça VA et al. Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011; 261: 139-143.
10. Munkholm K, Vinberg M, Kessing VL. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord 2013; 144: 16-27.
11. Tsai SY, Chen KP, Yang YY et al. Activation of indices of cell-mediated immunity in bipolar mania. Biol Psychiatry 1999; 45: 989-994.
12. Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596-602.
13. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263-267.
14. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
15. Anisman H, Hayley S, Turrin N, Merali Z. Cytokines as a stressor: implications for depressive illness. Int J Neuropsychopharmacol 2002; 5: 357-373.
16. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun 2011; 25: 221-229.
17. Cunha AB, Andreazza AC, Gomes FA et al. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2008; 258: 300-304.
18. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 952-955.
19. Chung KH, Tsai SY. Hyperinsulinemia associated with overweight medicated bipolar patients during full remission. Psychiatry Clin Neurosci 2010; 64: 620-624.
20. Tsai SY, Lee HC, Chen CC. Hyperinsulinaemia associated with β-adrenoceptor antagonist in medicated bipolar patients during manic episode. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1038-1043.
21. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5: 551-559.
22. Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001; 15: 2565-2571.
23. Birketvedt GS, Florholmen J, Sundsfjord J et al. Behavioral and neuroendocrine characteristics of the night-eating syndrome. JAMA 1999; 282: 657-663.
24. Chehab FF, Mounzih K, Lu R, Lim ME. Early onset of reproductive function in normal female mice treated with leptin. Science 1997; 275: 88-90.
25. Juge-Aubry CE, Somm E, Giusti V et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-1110.
26. Cheng TA, Williams P. The design and development of a screening questionnaire (CHQ) for use in community studies of mental disorders in Taiwan. Psychol Med 1986; 16: 415-422.
27. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
28. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 153: 429-435.
29. Strakowski SM, Tsai SY, DelBello MP et al. Outcome following a first manic episode: cross-national US and Taiwan comparison. Bipolar Disord 2007; 9: 820-827.
30. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
31. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; 30: 497-521.
32. Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-165.
33. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
34. Suvisaari J, Loo BM, Saarni SE et al. Inflammation in psychotic disorders: a population-based study. Psychiatry Res 2011; 189: 305-311.
35. Yekta D, Nathan HC, Walter SC et al. Meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67: 446-457.
36. Knijff EM, Breunis MN, Kupka RW et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord 2007; 9: 743-753.
37. Bulló M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor and leptin expression. Obes Res 2003; 11: 525-531.
38. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue adipocytes. Br J Nutr 2004; 92: 347-355.
39. Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-2610.
40. Opp M. Cytokines and sleep: the first hundred years. Brain Behav Immun 2004; 18: 295-297.
41. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999; 33: 1935-1942.
42. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application of clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
43. Tsai SY, Lee CH, Kuo CJ, Chen CC. A retrospective analysis of risk and protective factors for natural death in bipolar disorder. J Clin Psychiatry 2005; 66: 1586-1591.
44. Breuer HM. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin 2001; 17: 60-73.
45. Lee SY, Chen SL, Chang YH et al. Inflammation's association with metabolic profiles before and after a twelve-week clinical trial in drug-naïve patients with bipolar II disorder. PLoS ONE 2013; 8: e66847.
46. Pereira FO, Frode TS, Medeiros YS. Evaluation of tumour necrosis factor alpha, interleukin-2 soluble receptor, nitric oxide metabolites, and lipids as inflammatory markers in type 2 diabetes mellitus. Mediators Inflamm 2006; 1: 39062.
47. Straczkowski M, Kowalska I, Nikolajuk A et al. Plasma levels of soluble tumor necrosis factor-alpha receptors are related to total and LDL-cholesterol in lean, but not in obese subjects. Cardiovasc Diabetol 2006; 5: 14.
48. Schuld A, Kraus T, Haack M, Hinze-Selch D, Kuhn M, Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res 2000; 43: 164-166.
49. Pollmacher T, Hinze-Selch D, Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996; 16: 403-409.
50. Kenis G, Teunissen C, Jongh RD, Bosmans E, Steinbusch H, Maes M. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10, and CC16 in human serum. Cytokine 2002; 19: 228-235.